SGA Talent Present Women Leader From The Top BioTech & Pharma Companies.

For over 31 years it has been our focus to emphasis the importance of diversity and
inclusion by identifying, recruiting and engaging these highly accomplished
professionals
518 843-4611 www.sgatalent.com
SGA Talent Presents Women Leaders From The Top 10 Biotech
& Pharma Companies
February 2020

SGA Talent
Do you know who we know?
Recruitment Research
Recruiting
Staffing
Customized Competitive Intelligence
This report is limited to only a few women leaders
identified in a recent study SGA Talent completed last
year. The comprehensive study was to identify, map,
and profile leaders in the Biotechnology and
Pharmaceutical Industries three levels down from the
executive teams. It required the SGA Talent team to
create organization charts, compare/contrast all
identified to their peers, gather salary information and
show diversity and inclusion metrics.
If you are looking for talent or intelligence in these
industries, give us a call 518 843-4611.
For now let’s congratulate each of these highly
accomplished women.

SGA Talent Present Women Leaders From The Top 10 Companies In Biotech & Pharma
Amgen
Gilead Sciences
Celgene Corporation now part of Bristol-Myers Squibb
Biogen
Vertex
Illumina
Regeneron Pharmaceuticals
Alexion Pharmaceuticals
BioMarin Pharmaceuticals
Agilent Technologies
Pﬁzer
Johnson & Johnson
Roche
Abbvie
Gilead Sciences
Novartis
Amgen
Merck & Company
Sanoﬁ
Bristol-Myers Squibb

List Of Women Leaders & Profiles

The Top Women Leaders In Biotech of 2020
Amgen Victoria H. Blatter, Senior Vice President, U.S. Government Affairs
Amgen Judy Gawlik Brown, Senior Vice President Corporate Affairs
Amgen Tia Bush, Senior Vice President Quality
Amgen Lori Johnson, Executive Vice President Human Resources
Amgen Corinne Le Goff, Senior Vice President, General Manager, U.S General Medicine
Amgen Cynthia M. Patton,, Senior Vice President & Chief Compliance Officer
Amgen Arleen Paulino, Senior Vice President Manufacturing
Amgen Annalisa Pizzarello, Senior Vice President, Results Delivery Office
Amgen Susan Sweeney Senior Vice President, Global Product Strategy & Commercial Innovation

Gilead Jyoti Mehra, Gilead's Executive Vice President, Human Resources
Gilead Johanna Mercier, Chief Commercial Officer
Gilead Christi Shaw Chief Executive Officer, Kite
Gilead Taiyin Yang, Executive Vice President, Pharmaceutical Development and Manufacturing
Biogen Susan H. Alexander Executive Vice President, Chief Legal Officer and Secretary
Vertex Carmen Bozic,, Executive Vice President , Global Medicines Development and Medical Affairs
Vertex Reshma Kewalramani, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, Chief Medical Officer
Vertex Nia Tatsis, Ph.D., Senior Vice President and Chief Regulatory Officer
Vertex Nina Devlin, Senior Vice President, Chief Communications Officer
Vertex Stephanie Franklin, Senior Vice President and Chief Human Resources Officer

Illumina Paula Dowdy Senior Vice President, General Manager of Commercial Operations, Europe, the Middle East and Africa
Illumina, Aimee Hoyt, Senior Vice President, Chief People Officer
Illumina Susan Tousi, Senior Vice President of Product Development
Illumina Gretchen Weightman, Vice President and General Manager, Commercial Operations for Asia Pacific and Japan
Regeneron Hanne Bak, Senior Vice President, Preclinical Manufacturing & Process Development
Regeneron Beth Levine, Senior Vice President, Associate General Counsel, Chief Compliance Officer
Regeneron Marion McCourt, Senior Vice President, Commercial
Regeneron Sally A. Paull, Senior Vice President, Human Resources
Alexion Tanisha Carino, Ph.D Executive Vice President, Chief Corporate Affairs Officer
Alexion Ellen Chiniara, J.D. Executive Vice President, General Counsel
Alexion Indrani Franchini, J.D. Executive Vice President, Chief Compliance Officer

Alexion Anne-Marie Law, Executive Vice President, Chief Human Experience Officer
Alexion Aradhana Sarin M.D. Executive Vice President, Chief Financial Officer
Alexion Rana Strellis Senior Vice President, Global Culture and Corporate Social Responsibility
BioMarin Amy Wireman, Group Vice President Of Human Resources
BioMarin Brinda Balakrishnan, M.D.PhD, Group Vice President Corporate and Business Development
Agilent Diana Chiu Vice President, Agilent Assistant General Counsel and Assistant Secretary
Agilent Nancy Lelicoff is Vice President of Regulatory Affairs, Quality Assurance and Clinical Affairs
Agilent Darlene Solomon Senior Vice President and Chief Technology Officer

Top Women Leaders In The Pharmaceutical Industry 2020
Pfizer Lidia Fonseca, Executive Vice President Chief Digital & Technology Officer
Pfizer Angela Hwang, Group President of Pfizer Biopharmaceuticals Group
Pfizer Dawn Rogers, Executive Vice President Chief Human Resources Officer
Pfizer Sally Susman, Executive Vice President, Chief Corporate Affairs Officer
Johnson & Johnson Ashley McEvoy, Executive Vice President Worldwide Chairman, Medical Devices
Johnson & Johnson Jennifer Taubert is Executive Vice President, Worldwide Chairman, Pharmaceuticals
Johnson & Johnson Kathy Wengel, Executive Vice President & Chief Global Supply Chain Officer

Roche Cristian Wilbur, Head of Group Human Resources
Roche Barbara Schadler, Head of Group Communications
Roche Bridget Boyle, Vice President, Human Resources, North America
Abbvie Laura J. Schumacher.Vice Chairman, External Affairs and Chief Legal Officer
Abbvie Azita Saleki-Gerhardt, Ph.D. Executive Vice President, Operations
Novartis Shannon Thyme Klinger, Group General Counsel
Bristol-Myers Squibb Sandra Leung Executive Vice President, General Counsel
Bristol-Myers Squibb Kathryn Metcalfe is Executive Vice President, Corporate Aﬀairs
Bristol-Myers Squibb Ann M. Powell is the Global Head of Human Resources
Bristol-Myers Squibb CeLois Steele Director, Global Diversity & Inclusion Partnership Engagement

Novartis Susanne Schaffert, President, Novartis Oncology
Novartis Marie-France Tschudin, President of Novartis Pharmaceuticals
Novartis Natacha Theytaz, Global Head, Novartis Business Assurance & Advisory, Head, Internal Audit
Merck Julie Gerberding, Executive Vice President, Chief Patient Officer, Strategic Communications, Global Public Policy & Population Health
Merck Jennifer Zachary, Executive Vice President,, General Counsel
Sanofi Caroline Luscombe, Executive Vice President, Human Resources
Sanofi Kathleen Tregoning, Executive Vice President, External Affairs
Bristol-Myers Squibb Severine Lacourt Chief of Staff to the Chief Executive Officer

Women In
Biotechnology &
Pharma
Do you know who we know?
For over 31 years it has been our focus
to emphasis the importance of diversity
and inclusion as it relates to the talent
pool and candidate pipeline. It Matters!

Meet SGA Talent’s
Top Women Leaders In Pharma
& Biotech

Amgen
Victoria Blatter, Senior Vice President U.S. Government
Affairs
As senior vice president, U.S. Government Affairs, Victoria H. Blatter is responsible for federal and state legislative issues and managing
relationships with U.S. agencies, legislatures, and governmental administrations. She is also responsible for international lobbying and diplomacy in
Washington, D.C.
Prior to joining Amgen, Blatter worked at Merck & Co., Inc. as vice president of U.S. Policy and Federal Government Relations. She previously
served as professional staff for the U.S. Senate Special Committee on Aging and as minority staff director for the U.S. House Select Committee on
Aging—Subcommittee on Retirement Income and Employment.
Blatter received her bachelor of arts from Binghamton University and a master's degree in public administration from the Maxwell School of
Citizenship and Public Affairs at Syracuse University. She has worked in the pharmaceutical and biotechnology industry for more than 15 years.

Amgen
Judy Gawlik Brown, Senior Vice President Corporate
Affairs
Judy Gawlik Brown is senior vice president, Corporate Affairs. Brown is responsible for strategic internal and external communications, issues and reputation
management, philanthropy, and advocacy relations. Additionally, she serves as site head for Amgen’s corporate headquarters in Thousand Oaks, California.
Brown joined Amgen in 2017 as senior vice president, Global Business Solutions and Finance, responsible for the Global Business Solutions, Global Internal
Audit, Tax and Treasury organizations.
Before joining Amgen, Brown served as executive vice president of Business Operations and chief financial officer at Perrigo Company, where she led
Finance, IT, Accounting, Treasury, Tax, Global Product Portfolio, Corporate Development/M&A, Strategic Planning, Investor Relations, Corporate
Communications and Government Affairs.
Prior to Perrigo, she held progressive Finance, Global Product Development and Brand Marketing leadership positions in Italy and the U.S. for Whirlpool
Corporation. She began her career in the Chicago office of Ernst & Young and continued as an expatriate in Germany in Audit and Mergers & Acquisitions
practices.
She is a member of the Board of Directors of Belden Corporation, serving on its Audit and Finance committees. Brown is a Certified Public Accountant and
received her MBA from the University of Chicago and a BS in Accountancy from the University of Illinois at Urbana-Champaign.

Amgen
Tia Bush, Senior Vice President Quality
Tia Bush became Amgen’s senior vice president, Quality, responsible for all aspects of Quality Assurance, Quality Control, Quality Compliance, and
Environment, Health, Safety and Sustainability in 2018.
Prior to this role, Bush served as vice president, Site Operations at Amgen Rhode Island and Amgen Woburn from 2016 to 2018. Earlier, she served
as vice president, Quality at Amgen Manufacturing Limited in Puerto Rico, for more than four years. Since joining Amgen in 1993, Bush has also
held a variety of roles in Quality Assurance and Validation in Thousand Oaks, Colorado and Rhode Island.
Bush earned a Bachelor of Science degree in biology from the University of Southern California.

Amgen
Lori Johnson, Executive Vice President Human Resources
Lori Johnston is executive vice president, Human Resources, responsible for overseeing Amgen’s global Human Resources function. Prior to coming to
Amgen in 2016, Johnston led the Human Resources function for the Celanese Corporation, serving as executive vice president and chief administrative
officer. She was also responsible for Government Affairs, Global Communications, the Celanese Foundation and the company’s global community
engagement programs and diversity and inclusion efforts.
Before joining Celanese, Johnston spent more than 10 years with Amgen in progressive leadership positions, including as vice president, International
Human Resources. She also led the company’s global talent function with responsibility for senior talent attraction and development, leader and staff
development and diversity initiatives.
Earlier in her career, Johnston spent more than a decade with Dell Inc. in Human Resources and other business roles and also worked at the Michael & Susan
Dell Foundation as head of Human Resources.
Johnston received a master’s degree in Human Sciences from Our Lady of the Lake University in San Antonio, Texas, and a bachelor’s degree in Psychology
from the University of Central Oklahoma in Edmond, Oklahoma.

Amgen
Corinne Le Goff, Senior Vice President, General Manager, U.S
General Medicine
Corinne M. Le Goff became Amgen’s senior vice president, General Manager, U.S. General Medicine in March 2019. Prior to this role, Le Goff served
as senior vice president, Global Product Strategy and Commercial Innovation. She joined Amgen in 2015 as senior vice president, Regional General
Manager, Europe.
Before joining Amgen, Le Goff was president of Roche’s French affiliate. Prior to her role in France, she spent five years in strategic commercial
leadership roles managing large therapeutic areas at both Roche, where she was senior vice president of Global Product Strategy for the Neurosciences
franchise, and at Merck Serono, where she was senior vice president of Strategy and Global Marketing for Neurology, Rheumatology, and
Immunology. Prior to Merck Serono, Le Goff was senior vice president of U.S. Commercial Operations Empowered Regions at Sanofi-Aventis.
Le Goff received a Pharm. D. from the University Paris V and an MBA in Marketing from La Sorbonne University, France.

Amgen
Cynthia M. Patton, Senior Vice President & Chief Compliance Officer
Cynthia M. Patton serves as senior vice president and chief compliance officer, responsible for Amgen’s global privacy, trade and compliance organization.
Patton joined Amgen in 2005 and was a vice president in the Amgen law department with responsibility for commercial legal activities in the United States.
Prior to that position, she served as the lead commercial lawyer for both the oncology and inflammation business units.
Before joining Amgen, she spent seven years as general counsel of SCAN Health Plan, a California Health Maintenance Organization (HMO). Prior to
SCAN, Patton served as assistant general counsel of UniHealth and as a staff attorney in the Division of Enforcement at the SEC. She began her legal career
at Atlanta-based Alston & Bird in 1986 before moving to Los Angeles to work in law firms specializing in healthcare corporate and securities law.
Patton is dedicated to the development of upcoming talent and giving back. She serves as Chair of the Amgen Foundation and as a board member for the
Ethics and Compliance Initiative, Martin Luther King, Jr. Community Hospital in Los Angeles, and the Los Angeles Music Center. Patton is passionate
about education and serves as a member of the Board of Trustees of Vassar College, Wildwood School, and The National Association for Law Placement
Foundation. Patton received her juris doctor from George Washington University and her bachelor’s degree from Vassar College

Amgen
Arleen Paulino, Senior Vice President Manufacturing
Arleen Paulino, senior vice president, Manufacturing, leads Amgen’s commercial manufacturing organization. Prior to this role, Paulino served as vice
president, Site Operations at Amgen Singapore Manufacturing from 2016 to 2018, where she led the team to the successful licensure of Amgen’s ﬁrst
Next-Generation Biomanufacturing plant.
Paulino joined Amgen in 2002 and over the years has held various positions with increasing responsibility in Process Engineering and Process Development.
She was also the head of Clinical Operations and Development Supply Chain, where she was responsible for the end-to-end supply chain for the manufacture
and delivery of clinical product to support Amgen’s global clinical trials.
She began her career in Operations at Genentech and later joined Immunex, where she held a variety of roles overseeing development and scale-up
operations, contract manufacturing and technology transfer, as well as plant manager for the cell culture facility.
Paulino holds a Bachelor of Science degree in Biochemistry from Marquette University.

Amgen
Annalisa Pizzarello, Senior Vice President of the Results
Delivery Office
Annalisa Pizzarello, senior vice president of the Results Delivery Office, leads Amgen’s Full Potential program, partnering with the Functional
Transformation Offices, governance committees and global stakeholders to continue to accelerate the company’s transformation capabilities. Prior to
this role, Pizzarello was vice president of Commercialization and R&D Compliance, responsible for Amgen's end-to-end drug development and
portfolio management processes.
Before joining Amgen in 2008, Pizzarello led quality and compliance groups in manufacturing and pharmacovigilance at Wyeth. Earlier in her career,
she worked as associate chief counsel at the FDA and as a pharmaceutical, device and biotech attorney at the Washington DC law firm of Arnold &
Porter.
Pizzarello earned a Juris Doctor from the University of Chicago Law School, and she received a master’s degree in bioethics/philosophy and
bachelor’s degrees in philosophy and Russian studies from Brown University.

Amgen
Susan Sweeney Senior Vice President, Global Product
Strategy & Commercial Innovation
Susan Sweeney is senior vice president, Global Product Strategy & Commercial Innovation. She joined Amgen in September 2019. As the SVP for Global
Product Strategy and Commercial Innovation, Sweeney is responsible for providing commercial leadership for Amgen products at all stages of the product
lifecycle and for maximizing value across the portfolio. In addition, Sweeney will ensure that commercial insights translate into global product strategies,
and accelerate our commercial innovative capabilities, including “beyond the drug” solutions for improving patient and customer experience.
Sweeney came to Amgen from Bristol-Myers Squibb (BMS), where she led commercial activities as President of U.S. Commercial. She joined BMS in 1995
and built a legacy of industry leadership over nearly 24 years, driving sustained growth for many of the company’s most successful medicines.
A history of product growth and success, paired with a passion for mentoring other women in the ﬁeld, has earned Sweeney recognition as a leading
biopharmaceutical executive. Modern Healthcare named her one of its Top 25 Women Leaders, and FiercePharma included her on its list of Fiercest Women
in Life Sciences.

Gilead
Jyoti Mehra, Gilead's Executive Vice President of Human
Resources
Jyoti Mehra, Gilead's Executive Vice President of Human Resources, is responsible for leading people strategy and, together with the Gilead
Leadership Team, building an inclusive and collaborative culture. In her role, she has responsibility for elevating team performance and developing a
cohesive approach to attracting, developing and retaining employees.
Jyoti brings extensive experience in business partnership and organizational design to her current position. Prior to joining Gilead in 2017, Jyoti held
senior leadership positions with Novartis Corp. in the United States, Europe and China, bringing a broad international perspective to her work.
Jyoti received her bachelor’s degree in political science from Delhi University and her master’s degree in international studies from Jawaharlal Nehru
University.

Gilead
Christi Shaw Chief Executive Oﬃcer of Kite
Christi Shaw serves as Chief Executive Oﬃcer of Kite, Gilead's cell therapy company. Based in Santa Monica, California, Kite is pursuing the
ambitious goal of a cure for cancer with industry-leading pipeline and manufacturing capabilities. In her role, Christi is responsible for all cell
therapy operations around the world.
Before joining Gilead in 2019, Christi held senior executive positions at Eli Lilly & Co. and Novartis Corp. Her leadership has spanned a broad range
of therapeutic areas, including oncology.
Christi holds a bachelor's degree in business administration from Iowa State University and an MBA from the University of Wisconsin.
In 2016, she founded the More Moments More Memories Foundation, which assists patients with cancer and their families. Christi currently serves
on the board of directors of the Biotechnology Innovation Organization, Avantor and the Healthcare Women's Business Association.

Gilead
Johanna Mercier serves as Gilead's Chief Commercial Officer
Johanna Mercier serves as Gilead's Chief Commercial Officer, with responsibility for the global commercialization of all the company's medicines
throughout the product lifecycle. Under her leadership, Gilead works to ensure that patients around the world have access to the company's
transformational medicines.
Johanna joined Gilead in 2019 after 25 years at Bristol-Myers Squibb, where she served in a number of executive leadership positions, gaining broad
experience across geographies and in all aspects of the commercial business. In her time there, she successfully evolved the culture and drove strong
commercial execution with double-digit growth and multiple launches that changed the standard of care in melanoma and renal cancers.
Johanna holds a bachelor's degree in biology from the University of Montreal and an MBA from Concordia University.She is a member of the board of
the University of Southern California's Leonard D. Schaeffer Center for Health Policy and Economics.

Gilead
Taiyin Yang Executive Vice President of Pharmaceutical
Development and Manufacturing
Taiyin Yang serves as Executive Vice President of Pharmaceutical Development and Manufacturing with responsibility for all the company's
investigational compounds and marketed products. Under her leadership, Gilead developed the world's ﬁrst HIV single tablet regimen and advanced
more than 25 compounds from early-stage development to market, reaching millions of people around the world.
Prior to joining Gilead in 1993, Taiyin worked in analytical chemistry at Syntex Corp.
She received her bachelor's degree in chemistry from National Taiwan University and her PhD in organic chemistry from the University of Southern
California.

Biogen
Susan H. Alexander Executive Vice President, Chief
Legal Officer and Secretary
Susan H. Alexander, Executive Vice President, Chief Legal Officer and Secretary of Biogen, and has served on the Executive Committee since 2006.
Prior to that, from 2006 to December 2011, Ms. Alexander served as our Executive Vice President, General Counsel and Corporate Secretary. From
2003 to January 2006, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International
Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms. Alexander served as General Counsel of IONA Technologies, a
software company. From 1995 to 2001, Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials
company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. Ms. Alexander received her
B.A. from Wellesley College and her J.D. from Boston University School of Law.

Biogen
Ginger Gregory, Ph.D., is Executive Vice President and Chief
Human Resource Officer
Ginger Gregory, Ph.D., is Executive Vice President and Chief Human Resource Officer of Biogen and has served on the Executive Committee since
July 2017. Dr. Gregory joined Biogen from Shire PLC, where she had served as Executive Vice President and Chief Human Resources Officer since
2014.
Prior to joining Shire, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries,
including Dunkin’ Brands, where she served as Chief Human Resource Officer; Novartis, AG, where she was the division head of Human Resources
for Novartis Vaccines and Diagnostics, Novartis Consumer Health, and Novartis Institutes of BioMedical Research from 2005-2012; and Novo
Nordisk, where she served as Senior Vice President, Corporate People & Organization at the company’s headquarters in Copenhagen, Denmark.
Earlier in her career, she held a variety of human resources generalist and specialist positions at Bristol Myers Squibb and served as a consultant with
Booz Allen & Hamilton in the area of organization change and effectiveness.
Dr. Gregory is a graduate of the University of Massachusetts and The George Washington University with a B.A., M.Phil. and Ph.D. in Psychology.

Vertex
Carmen Bozic, M.D., Executive Vice President of Global Medicines
Development and Medical Affairs (GMDA)
Carmen Bozic, M.D., joined Vertex in 2019 and is the company’s Executive Vice President of Global Medicines Development and Medical Affairs (GMDA).
In this role, Dr. Bozic oversees clinical development, medical affairs, drug safety, global clinical operations, biometrics, and other related functions and is
responsible for developing and driving execution of Vertex’s clinical development programs.
Prior to Vertex, Dr. Bozic spent more than 20 years at Biogen where she held positions of increasing responsibility, including as Senior Vice President of
Global Development, an organization of more than 500 people in the US, Europe and Japan. During her tenure at Biogen, she led multiple functions including
Global Clinical Development, Safety, Preclinical Safety, Regulatory, Clinical Operations and Biometrics. She has deep experience leading global clinical
development programs across all phases of development, as well as multiple diseases and therapeutic modalities. Dr. Bozic has overseen the development,
regulatory filings and approvals of several therapies, including TYSABRI® (natalizumab), AVONEX® (interferon beta-1a) pre-filled syringe and
auto-injector, FAMPYRA® (fampridine), TECFIDERA® (dimethyl fumarate), PLEGRIDY® (pegylated interferon beta-1a), and ZINBRYTA® (daclizumab)
for the treatment of multiple sclerosis; ELOCTATE® (Factor VIII Fc fusion protein) and ALPROLIX® (Factor IX Fc fusion protein) for the treatment of
severe Hemophilia A and B; and SPINRAZA® (nusinersen) for the treatment of spinal muscular atrophy.
Dr. Bozic was the industry representative to the FDA’s Risk Communication Advisory Committee and was a member of PhRMA’s Clinical and Preclinical
Development Committee. She is a member of the Clinical Advisory Committee at Akili Interactive. She received her medical degree from McGill University,
where she also completed her residency in internal medicine and served as Chief Resident. She also completed a combined fellowship in Pulmonary and
Critical Care Medicine at Brigham and Women’s and Beth Israel Deaconess Hospital. Dr. Bozic conducted research at the Ina Sue Perlmutter Cystic Fibrosis
Research Laboratory at Boston Children’s Hospital, focusing on the role of chemokines and neurokinins in inflammatory responses. She was an Associate
Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical industry.

Vertex
Reshma Kewalramani, M.D., FASN, Executive Vice President, Global
Medicines Development and Medical Affairs, and Chief Medical
Officer
Reshma Kewalramani, M.D., FASN, joined Vertex in 2017 and is the company’s Executive Vice President, Global Medicines Development and Medical
Affairs, and Chief Medical Officer. In this role, Dr. Kewalramani oversees clinical development, global regulatory affairs, medical affairs, drug safety and
other related functions and is responsible for developing, advising and driving execution of Vertex’s clinical development programs.
Prior to Vertex, Dr. Kewalramani spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice
President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, U.S. Medical Organization, a group she established
and grew to assume responsibility for the full portfolio of molecules across six therapeutic areas.
Dr. Kewalramani is the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee and was on the inaugural Board of Directors
of the Kidney Health Initiative. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in
Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani received her medical degree,
with honors, from the Boston University School of Medicine and is also an alumnus of the Harvard Business School.

Vertex
Nia Tatsis, Ph.D., Senior Vice President and
Chief Regulatory Officer
Nia Tatsis, Ph.D., joined Vertex in 2017 and is the company’s Senior Vice President and Chief Regulatory Officer. In this role, she provides global
regulatory leadership and is responsible for managing all regulatory interactions involving the research and development, manufacturing, and
commercialization of Vertex’s transformational medicines. In addition to creating and executing the company’s global regulatory strategy, Dr. Tatsis
also manages a worldwide team of regulatory professionals.
Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer, and
Wyeth. Most recently, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit focused on
Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology, and Oncology/Immuno-Oncology.
Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and
completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology
from the University of Vermont and also holds a B.S. in Biology from Temple University.

Vertex
Nina Devlin, Senior Vice President and Chief Communications Officer
Nina Devlin joined Vertex in 2019 as Senior Vice President and Chief Communications Officer. In this role, she is responsible for leading the global
corporate communications function, spanning product communications, media relations, digital and social communications, internal communications,
corporate social responsibility and community affairs.
Ms. Devlin joined Vertex from the U.S. Food and Drug Administration (FDA), where she served as senior communications advisor to FDA
Commissioner Scott Gottlieb. Prior to this, Ms. Devlin spent seven years as the Head of Global Communications for Mylan NV, one of the world’s
largest generics and specialty pharmaceutical companies, overseeing external, financial, digital and internal communications, as well as the company’s
corporate social responsibility program. Before Mylan, Ms. Devlin spent 15 years at leading global communications agencies, including Edelman and
Brunswick Group.
Ms. Devlin received her bachelor’s degree in international relations from Georgetown University’s School of Foreign Service.

Vertex
Stephanie Franklin is the Senior Vice President and
Chief Human Resources Officer
Stephanie Franklin is the Senior Vice President and Chief Human Resources Officer (CHRO) at Vertex. She oversees all global aspects of human resources,
including Talent Acquisition, Total Rewards, Global Organization & Leadership Development, HR Business Partners, Engagement and Diversity &
Inclusion.
Prior to joining Vertex in August of 2017, Stephanie was SVP, Global Human Resources at Nuance Communications where she was responsible for the HR
Business Partner & Global HR Operations functions, Talent & Organizational Development and M&A. Before Nuance, Stephanie was the Vice President of
Talent & Integrated HR Solutions at Blue Cross Blue Shield of Massachusetts and spent twelve years at Procter & Gamble.
Stephanie is a business-focused, results oriented executive with over 20 years of experience in diverse industries and geographies who invests in designing &
implementing successful HR strategies that enable organizations to achieve their unique potential. She is a leader in the community as Board Member and
President of the Human Resources Leadership Forum (HRLF), a member and former Board Chair of the Boston-Manchester March of Dimes, and a member
of the Bottom Line Massachusetts Regional Advisory Board. Stephanie was also co-founder & leader of the Procter & Gamble Boston Women’s Network, a
senior mentor for the Women Unlimited Leadership Development Program, and Vice Chair of the United Way of Massachusetts Bay Healthy Childhood
Development Initiative.
Stephanie holds a B.A. in Psychology and M.A. in Corporate and Organizational Communications from Western Kentucky University. She worked there as
an Adjunct Professor in the Department of Communications prior to moving into the field of Human Resources.

Illumina
Paula Dowdy Senior Vice President and General Manager of
Commercial Operations for Europe, the Middle East and Africa
Paula Dowdy is the Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa. Since joining
Illumina in August 2016, Dowdy has reorganized the business, identiﬁed new markets and returned the region to sustainable growth. In addition,
Dowdy played a pivotal role as a senior leader with the launch of the NovaSeq.
Previously, Dowdy was Senior Vice President for Cloud, Software, and Managed Services at Cisco where she drove numerous innovative
solutions. During her 20-year tenure at Cisco, she held numerous leadership roles, spearheading product, software and service groups for virtually
all customer segments. Having spent the majority of her career in Europe, Dowdy currently resides in London.
Dowdy holds a Master of Business Administration from Pepperdine University and an undergraduate degree from the University of California,
Berkeley.

Illumina
Aimee Hoyt, Senior Vice President and Chief People
Officer
Aimee Hoyt is Senior Vice President and Chief People Officer at Illumina, where she is responsible for all aspects of the company’s HR strategies.
Hoyt has a successful track record for leading workforce transformation, driving business growth and creating high-impact teams.
Previously, she has held senior positions at some of the world’s best-known technology companies including Hewlett-Packard, Cisco and Sun
Microsystems. Most recently, she was the Chief Human Resources Officer at Rackspace, a leading managed cloud computing company, in San
Antonio, Texas. She led the HR team and was responsible for helping build, align and develop high-performing global teams. During her tenure,
Rackspace was recognized as one of Fortune’s 100 Best Companies to Work For, Top 30 Best Places in Tech and Great Places to Work for
Millennials.
Hoyt earned a master’s in human resource development from the Rochester Institute of Technology.

Illumina
Susan Tousi, Senior Vice President of Product
Development
Susan Tousi is Senior Vice President of Product Development at Illumina, where she is responsible for global engineering, consumables, sequencing
applications, software and informatics development efforts, ensuring Illumina’s scientists and engineers continue the culture of innovation and
product excellence that has been a hallmark of Illumina.
Tousi has more than 25 years of R&D and business leadership at Fortune 100 technology companies and within the life sciences industry. Formerly,
Tousi was as a Corporate Vice President and General Manager for Eastman Kodak’s Consumer Inkjet Systems organization. Prior to joining Kodak,
Tousi was an R&D program manager for Phogenix Imaging LLC, a joint venture start-up of Hewlett-Packard and Kodak. She previously spent 10
years with Hewlett-Packard in technical and management roles. Tousi played a significant role in the 2017 launch of the NovaSeq Series at Illumina
and in 2018 was elected to the National Academy of Engineers for this effort to make genomics accessible and increasing throughput and enabling
the path to the $100 human genome.
Tousi holds an MBA degree from UCLA and a BS in Engineering Science and Mechanics from Pennsylvania State University.
Tousi serves as a trustee at the world renowned La Jolla Playhouse.

Illumina
Gretchen Weightman, Vice President and General
Manager of Commercial Operations for Asia Pacific
and Japan
Gretchen Weightman is the Vice President and General Manager of Commercial Operations for Asia Pacific and Japan at Illumina. In her role,
Weightman is responsible for leading and developing the commercial organization within the region that includes Japan, Singapore, Australia, South
Korea, New Zealand, and India.
Weightman has held several leadership positions within Illumina prior to her current role. She was the Director of Sales for Asia Pacific, where she
was responsible for sales of the Asia Pacific region, overseeing five geographical districts for orders, shipments and revenue. Prior to this, Weightman
was the Senior Marketing Manager for South Asia Pacific, responsible for the overall marketing strategy and implementation in South East Asia,
India, Singapore, Australia, and New Zealand.
Prior to joining Illumina, Weightman worked at Applied Biosystems in a variety of commercial positions including Sales, Marketing, and Product
Management. Her professional career started at Genesis Research & Development where she set up the high-throughput sequencing facility.
Weightman graduated from Auckland University with a BSc in Molecular Genetics and a Diploma of Commerce.

Regeneron
Hanne Bak, Senior Vice President, Preclinical
Manufacturing & Process Development
Hanne Bak, Senior Vice President, Preclinical Manufacturing & Process Development
Hanne Bak, PhD, joined Regeneron in 2004 and serves as the Senior Vice President, Preclinical Manufacturing & Process Development (PMPD). Dr.
Bak started her career at Regeneron as a research engineer working in the Puriﬁcation Development group within PMPD and subsequently held roles
of increasing responsibility moving up to Vice President. Dr. Bak received her BS, MS and PhD in Chemical Engineering from Danmarks Tekniske
Universitet (Technical University of Denmark).

Regeneron
Beth Levine Senior Vice President, Associate
General Counsel, Chief Compliance Officer
Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer.
Prior to joining Regeneron, Ms. Levine spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division,
culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General
Counsel and Chief Compliance Officer. In the early days of her legal career, Ms. Levine was a litigation associate at the law firm of Paul,
Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New
York. Ms. Levine received a BS from Cornell University and a JD from Fordham Law School.

Regeneron
Marion McCourt, Senior Vice President and Head of Commercial
Organization
Marion McCourt joined Regeneron in 2018 and serves as Senior Vice President and Head of the Commercial organization. Prior to joining
Regeneron, Marion was at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as
Chief Operating Officer of Medivation until it was acquired by Pfizer in 2016, and before that held commercial leadership roles at Amgen, including
Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care
business unit. Marion began her career—and spent 12 years—at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She
received her BS from Lafayette College.

Regeneron
Sally A. Paull, Senior Vice President
Human Resources
Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief
Human Resources Oﬃcer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources Oﬃcer at Forest
Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BS
from the United States Air Force Academy and her Master’s in International Relations from the University of Delaware.

Alexion
Tanisha Carino, Ph.D Executive Vice President,
Chief Corporate Affairs Officer
Tanisha Carino, Ph.D. Executive Vice President, Chief Corporate Affairs Officer
Tanisha Carino, Ph.D., is Executive Vice President, Chief Corporate Affairs Officer of Alexion. In this role, Dr. Carino is responsible for global
government relations, policy and communications.
Prior to joining Alexion, Dr. Carino served as Executive Director of FasterCures, a Center of the Milken Institute, a nonpartisan think tank whose
mission is working with global government, philanthropic, and business leaders to accelerate treatments to patients. Prior to leading FasterCures, Dr.
Carino was an executive at GlaxoSmithKline where she led the United States policy function, and spent over a decade with Avalere Health, a strategic
advisory services organization, where she worked with senior leaders of life sciences companies to maximize opportunities and mitigate challenges
related to biomedical research and patient access. She also worked in the U.S. Medicare program to improve access for its beneficiaries and support the
development of real-world evidence.
Dr. Carino is a Fulbright Fellow, earned her Ph.D. in health policy from Johns Hopkins University, and is associate faculty at the Johns Hopkins
Bloomberg School of Public Health.

Alexion
Ellen Chiniara, J.D. Executive Vice President General Counsel
Ellen Chiniara, J.D.Executive Vice President, General Counsel
Ellen Chiniara is Executive Vice President, General Counsel, Corporate Secretary, she is responsible for overseeing all global legal matters for
the Company. Prior to joining Alexion in January 2018, Ms. Chiniara was Senior Vice President and General Counsel of Alere Inc., a point-of-care
diagnostics company, from October 2006 to October 2017 where she was responsible for all legal matters and, from June 2014 to October 2017 she
had oversight of compliance and government affairs matters. She managed the legal aspects of the company’s numerous acquisitions and dispositions
and was also the executive sponsor of Alere’s corporate social responsibility efforts. Prior to joining Alere, Ms. Chiniara served as Associate General
Counsel for Serono’s Neurology division from 2002 to 2006. Earlier in her career, Ms. Chiniara was a partner at the law firm Hale and Dorr LLP
(now Wilmer Cutler Pickering Hale and Dorr LLP). Ms. Chiniara received her J.D. from Stanford University’s School of Law and her Bachelor's
Degree from Bryn Mawr College. She also was a graduate fellow at Yale University in Slavic Languages.

Alexion
Indrani Franchini, J.D. Executive Vice President, Chief
Compliance Officer
Indrani Franchini J.D. Executive Vice President, Chief Compliance Officer
Indrani Franchini, J.D., is Executive Vice President, Chief Compliance Officer of Alexion. Ms. Franchini is responsible for leading Alexion’s global
compliance program and co-leads the Global Corporate Compliance Committee.
Ms. Franchini has extensive experience developing and building the infrastructure and company-wide standards for global compliance programs.
Prior to joining Alexion, Ms. Franchini served as Chief Compliance Officer at Hess Corporation. She previously spent nearly ten years with Pfizer
overseeing all compliance elements for the development, marketing, and promotion of its global business. Earlier in her career, Ms. Franchini served
as an attorney with Milbank, Tweed, Hadley & McCloy in the firm’s New York and Tokyo offices.
Ms. Franchini earned her J.D. from the University of Michigan Law School and a Bachelor of Arts from Princeton University. In addition, she spent
a year as a Fulbright Fellow at the Kyushu University Graduation School in Fukuoka, Japan.

Alexion
Anne-Marie Law, Executive Vice President,
Chief Human Experience Officer
Anne-Marie Law, Executive Vice President, Chief Human Experience Officer
Anne-Marie Law is Executive Vice President, Chief Human Experience Officer of Alexion. She is responsible for Human Resources, Patient
Advocacy, and Digital & IT globally, with the goal of turning patient insights into action and cultivating world-class leadership and innovation
capabilities across the organization to advance Alexion’s strategy and elevate the patient experience.
Ms. Law brings more than 25 years of experience at global corporations to the organization. Prior to joining Alexion, she served as Chief Human
Resources Officer at Hyatt Hotels Corporation, where she was responsible for building the strategy to support the company’s 100,000 employees
worldwide, and designing talent systems to create world class leadership and customer connectivity capabilities. She previously served as Executive
Vice President and Head of Human Resources for Baxalta Incorporated, and held various senior human resources positions at McKesson
Corporation, including the Specialty Health Division, VeriSign, and Xilinx, Inc.
Ms. Law is a graduate of Leicester University with a degree in Art History in the United Kingdom and the National College of Ireland, Dublin.

Alexion
Aradhana Sarin M.D. Executive Vice President,
Chief Financial Officer
Aradhana Sarin M.D. Executive Vice President, Chief Financial Officer
Aradhana Sarin, M.D., is Executive Vice President, Chief Financial Officer. In this role, she is responsible for overseeing global financial
management, treasury, internal audit, corporate strategy, business development, investor relations, security activities, and business operations,
including corporate planning, at Alexion.
Dr. Sarin joined Alexion in November 2017 to drive strategy and business development, and she served as Alexion’s Chief Business and Strategy
Officer prior to becoming the Chief Financial Officer. She brings to Alexion more than 20 years of professional experience at global financial
institutions. Dr. Sarin has extensive knowledge of global healthcare systems, and has closed more than 100 transactions across M&A, equity and debt
financing transactions. Prior to joining Alexion, Dr. Sarin was Managing Director of Healthcare Corporate & Investment Banking at Citi Global
Banking, focusing on clients in the life sciences and biopharmaceutical sectors. Before this, she served as Managing Director of Healthcare
Investment Banking at UBS, and worked at JP Morgan in the M&A Advisory and Healthcare groups focusing on transaction execution. Before her
banking career, Dr. Sarin trained as a medical doctor in India and spent two years practicing in both India and Africa. Dr. Sarin also serves on the
Board of OraSure Technologies, Inc.
Dr. Sarin completed her medical training at the University of Delhi and received her MBA from Stanford Business School.

Alexion
Rana Strellis Senior Vice President, Global Culture
and Corporate Social Responsibility
Rana Strellis Senior Vice President, Global Culture and Corporate Social Responsibility
Rana Strellis is Senior Vice President, Global Culture and Corporate Social Responsibility of Alexion. Prior to joining Alexion in April 2017, Ms. Strellis
served as Senior Vice President, Global Communications, Culture, and Diversity and Inclusion for Baxalta. In this role, Ms. Strellis created and executed a
culture transformation vision, diversity and inclusion strategy, and a corporate brand reputation plan. Prior to Baxalta, she held progressive roles of
responsibility at Baxter Healthcare in Strategy and Business Operations, Marketing, and Human Resources in both the U.S. and Europe.
As Global Head of Strategy and Business Operations at BioScience for Baxter Healthcare, Ms. Strellis led the creative campaign to elevate the brand proﬁle
as a premier biotech organization. Additionally, she served as the Channel Marketing Leader for GAMMAGARD® and led the development of a channel
value proposition platform that drove brand preference for GAMMAGARD®and Albumin. As the Marketing HYQVIA Operations Leader at BioScience,
Ms. Strellis also successfully led the cross-functional steering committee to implement a best-in-class launch for U.S. HyQvia. Prior to her marketing roles,
Ms. Strellis held Human Resources management positions for various domestic and global Baxter divisions.
Ms. Strellis received a master’s degree in Industrial & Labor Relations from Cornell University, and a bachelor’s degree in Economics from the University of
Illinois.

BioMarin
Amy Wireman, Group Vice President
Of Human Resources
Amy Wireman joined BioMarin in 2013 and currently serves as the Group Vice President of Human Resources. In her role, Amy is responsible for
managing all HR teams, including HR business partners, regional HR teams, learning and development, talent acquisition, compensation and
beneﬁts, and HR systems and operations.
Prior to holding positions of increasing responsibility within BioMarin, Amy held leadership positions within HR at Wind River, Xyratex and
Micromuse, as well as senior consulting roles with Watson Wyatt and Mercer. She is a graduate of New York University where she earned degrees in
both Mathematics and Spanish.

BioMarin
Brinda Balakrishnan, M.D.PhD, Group
Vice President Corporate and Business Development
Brinda Balakrishnan, M.D., Ph.D., joined BioMarin in early 2016 and currently serves as Group Vice President, Corporate and Business
Development. She leads the company’s initiatives on corporate strategy, mergers and acquisitions, and licensing.
Prior to BioMarin, Dr. Balakrishnan was the Co-founder and Vice President of Corporate Strategy and Product Development at Vision Medicines,
Inc., a start-up focused on developing treatments for rare ophthalmic diseases. In that role, she was responsible for in-licensing assets from big
pharma and academia, fund-raising, and advancing a program for the treatment of Stargardt Disease. Before Vision Medicines, she spent two years as
a consultant at McKinsey & Company in the healthcare practice serving clients across small biotech, large pharma, and provider groups on topics
related to corporate strategy, corporate and business development, and operations. Prior to McKinsey, Dr. Balakrishnan was in Business
Development at Genzyme.
Dr. Balakrishnan earned a Bachelor’s of Science degree from the Massachusetts Institute of Technology (M.I.T.) in Chemical Engineering and a
Ph.D. from M.I.T. in Biomedical Engineering and Chemical Engineering. She also earned her M.D. from Harvard Medical School and conducted her
medical training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, a Harvard hospital.

Agilent
Diana Chiu Vice President, Agilent Assistant General
Counsel and Assistant Secretary
Diana Chiu Vice President, Agilent Assistant General Counsel and Assistant Secretary
P. Diana Chiu is vice president, assistant general counsel and assistant secretary of Agilent Technologies. She is responsible for mergers and
acquisitions, corporate governance and securities matters. She joined Agilent in 2013 as senior counsel. Before that she worked at Pillsbury Winthrop
Shaw Pittman, LLP, a law ﬁrm in Palo Alto, California. There she represented public and private technology companies on a broad range of corporate
and securities matters. She was also seconded to Sumitomo Chemical Co. Ltd.’s legal department in Tokyo, where she managed an array of in-house
legal issues. Prior to that she was corporate counsel at Marvell Technology, Inc.
Chiu is a graduate of the University of Virginia School of Law. She also received a master's degree in health administration from the University of
Southern California and a bachelor’s degree in biochemistry from the University of California, Berkeley. She is an active member of the State Bar of
California.

Agilent
Nancy Lelicoff, Vice President of Regulatory Affairs, Quality Assurance
and Clinical Affair
Nancy Lelicoff is Vice President of Regulatory Affairs, Quality Assurance and Clinical Affairs for Agilent Technologies. She has responsibility
for developing, implementing and monitoring Agilent’s companywide regulatory compliance and quality programs. Lelicoff oversees a global
team of about 120 people.
Lelicoff joined Agilent in March 2014. Previously, she was Senior Vice President, Regulatory Affairs and Quality and Systems Test Engineering,
for Volcano Corp. Her prior roles include Vice President of Quality Assurance at Boston Scientific, and Director of Consumer Products Quality
and Regulatory Compliance at Becton Dickinson. She has more than 20 years of experience within the life sciences industry, most of which was
at Johnson & Johnson in various roles.
Lelicoff received a B.S. in mathematical engineering from the University of Arizona and a Master of Science in engineering and technical
management from West Coast University.

Agilent
Darlene Solomon Senior Vice President and Chief Technology Officer
Darlene Solomon is senior vice president and chief technology officer for Agilent Technologies. Her responsibilities include Agilent Research Laboratories which focuses on high
impact, longer range research in support of Agilent's sustained business growth, and Agilent's programs in university relations, external research and venture investment. In her leadership
role, she works closely with Agilent's businesses to define the company's technology strategy and R&D priorities.
She joined Hewlett-Packard Laboratories in 1984 as a research scientist and soon moved into leadership as the Research & Development Manager of their Chemical and Biological
Systems Department. When Agilent Technologies was spun off from H-P in 1999, she became responsible for Research and Development/Technology for Agilent's Life Sciences and
Chemical Analysis business. She was promoted to Vice President and Director of Agilent Laboratories in 2003, and has been Agilent Technologies' Chief Technology Officer and Senior
Vice President since 2006.
Solomon earned her bachelor's degree in chemistry from Stanford University and a doctorate in bioinorganic chemistry from the Massachusetts Institute of Technology, and she
completed Stanford University's Executive Development Program. Amongst the recognition for her accomplishments Solomon was elected to the National Academy of Engineering and
received the USC Viterbi School of Engineering's Daniel J Epstein Engineering Management Award. She was also elected Fellow, American Institute for Medical and Biological
Engineering, inducted into the Women in Technology International's Hall of Fame, received the YWCA Tribute to Women and Industry Award, and named to Corporate Board Member's
50 Top Women in Technology.
Solomon serves on the board of directors at Materion Corporation. She also participates in multiple academic and government advisory and review boards, including current and recent
appointments to the National Academies' Board on Chemical Sciences and Technology, Visiting Committee on Advanced Technology of the National Institutes of Standards and
Technology, Stanford Interdisciplinary Life Sciences Council, UC Berkeley's College of Engineering Advisory Board, and Singapore National Research Foundation's Scientific Advisory
Board.

Pfizer
Lidia Fonseca, Executive Vice President Chief Digital & Technology
Officer
Lidia Fonseca is Executive Vice President, Chief Digital and Technology Officer at Pfizer, responsible for developing and implementing an enterprise-wide digital strategy. Lidia leads all
digital, data and technology solutions across the company.
She spearheads several transformational programs and initiatives to support Pfizer’s purpose of delivering Breakthroughs that Change Patients’ Lives applying digital capabilities and products
including: digitizing drug discovery and development; improving health outcomes and patient experiences; improving operational processes through automation and robotics; and delivering
powerful insights with advanced data and analytics for better decision-making.
Lidia leads the effort to create Pfizer’s Advanced Analytics Platform that brings together data from Pfizer and external partners as well as tools to model scientific and clinical decisions,
patterns and insights. She is also driving initiatives to re-imagine clinical trials through robotics/automation and tech-enabled processes that enhance patient, provider and site experiences,
improve selection and recruitment, and reduce clinical trial cycle times.
Lidia led the effort to launch Pfizer’s Digital Companion™, a suite of digital products and solutions for every therapy to deepen engagement between patients and physicians for better
outcomes. She recently collaborated to deliver five Pfizer Digital Companions™: Mabu Wellness Coach for patients, Champix Chatbot to assist with smoking cessation, LivingWith app to
support patients, and their loved ones, undergoing cancer treatment, drone medicine delivery in the Dominican Republic to increase patient access to medicines in remote and difficult-to-reach
locations, and a partnership with Fitbit to drive timely diagnosis of atrial fibrillation.
She also leads initiatives to empower Pfizer colleagues, simplifying and automating their work with robotics, machine learning, and predictive analytics that enable better and faster decisions,
while driving efficiencies. In 2019, Pfizer automated 30 percent of approximately 100 million transactions across the company.
In her prior role, Lidia was the Senior Vice President and CIO at Quest Diagnostics, the world’s leading provider of diagnostic information services serving one in three American adults each
year, and half the physicians and hospitals in the U.S. She was responsible for technology, informatics and digital solutions. Lidia led the effort to create Quest's innovative Quanum Solutions
brand of healthcare IT and data analytics offerings that deliver critical insights to improve quality outcomes and patient care while lowering costs.
Lidia was named a Healthcare Transformer by Medical, Marketing & Media in 2019. In 2018, she was the only diagnostics provider executive to participate in the White House Artificial
Intelligence Summit. She received the 2017 Forbes CIO Innovation Award that recognizes CIOs who lead revenue enhancing innovation efforts. Lidia was a founding member of Synaptic
Health Alliance, that includes leading healthcare companies Aetna, Ascension Health, Humana, MultiPlan, Optum, Quest Diagnostics and United Health Group, using blockchain technology
to improve provider data quality, which will serve as a new distributed partnership model that can be used to tackle other industry-wide data issues.
Lidia is a member of the Board of Directors of Tegna, Inc. (NYSE: TGNA). She also was a board member of Q2 Solutions, a joint venture between Quest Diagnostics and IQVIA from 2016 to
2018. She earned a bachelor’s degree from the University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate
School of Business.

Pfizer
Angela Hwang, Group President of Pfizer
Biopharmaceuticals Group
Angela Hwang is a member of Pfizer’s Executive Team and Group President of the Pfizer Biopharmaceuticals Group, which comprises 80% of Pfizer’s
revenues. Her organization of 26,000 colleagues is responsible for bringing over 600 innovative medicines and products to patients. In 2019, more than 290
million people benefited from a Pfizer Biopharma medicine or vaccine to improve their health and, in some cases, save their lives. Altogether, Pfizer
Biopharma generated more than $38 billion in 2018 revenues.
As Group President of Pfizer Biopharma, Angela leads 7 commercial business units, reaching patients in more than 125 countries. Together, these businesses
strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care,
infectious diseases, and preventative care with vaccines.
Angela has been with Pfizer for 23 years, working across all geographies and therapeutic areas. She is motivated by the common purpose that all Pfizer
colleagues share, to bring breakthroughs to patients, regardless of where they are in the world. Her childhood as an Asian girl growing up in apartheid South
Africa, defined her worldview and underscored the importance of equity in everything she does today.
Angela sits on the boards of EFPIA (European Federation of Pharmaceutical Industries and Associations), as well as the Pfizer Foundation, a charitable
organization that addresses global health challenges. She has also been active in industry groups such as BIO, where she previously co-chaired the Vaccines
Policy Committee. In 2019, she was named in Crain’s Notable Women in Healthcare list.
Having always been curious about transformation and the art of the possible, in 2019, Angela launched Diverse Perspectives, a podcast series where she hosts
global thought leaders pioneering change across a variety of industries. You can learn more about Diverse Perspectives here, and subscribe on iTunes,
Spotify, and other streaming platforms.
Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and MBA from Cornell University. She is a
strong advocate for women’s leadership and sustainable global health equity.

Pfizer
Dawn Rogers, Executive Vice President of Chief Human
Resources Officer
Dawn Rogers has been named Executive Vice President of Human Resources at Pfizer, effective June 1, 2018. Her experience spans Pfizer’s global
business, including HR leadership roles in Commercial in both developed and emerging markets; Research and Development; and Enabling
Functions.
Dawn joined Pfizer in 1999 as Senior Director, HR Lead, for U.S. Sales. From 2000 to 2006, she played a key role in the integration of the field
forces during both the Warner-Lambert and Pharmacia acquisitions. From 2006 to 2008, Dawn was the VP of HR for Pfizer's European Commercial
Operations where she co-led the efforts to establish business units in Europe. From 2008 to 2011, she was a member of the WRD Leadership Team
where she led the Wyeth R&D integration and helped to build a world-class team of scientific talent. In 2011, Dawn was appointed SVP of HR for
the Primary Care Business Unit, where she co-led the restructuring of the commercial businesses and integration the emerging markets. In 2013, she
became the SVP of HR for the Global Innovative Pharma Business; and in 2016, SVP of HR for Pfizer Essential Health, Global Product
Development, and the Legal and Compliance Divisions. In November 2017, Dawn was appointed as the SVP of HR for the Chief Operating Officer
with responsibility for Commercial, Global Product Development, Pfizer Global Supply, Corporate Strategy, and Legal and Compliance.
Prior to joining Pfizer, Dawn spent 11 years in Human Resources at Serono and three years at Kos Pharmaceuticals, a start-up company, where she
built their commercial organization in preparation for the first product launch and an IPO. She holds a BA in Psychology and an MA in Management.

Pfizer
Sally Susman, Executive Vice President &
Chief Corporate Affairs Officer
Sally Susman is Executive Vice President and Chief Corporate Affairs Officer at Pfizer. She chairs Pfizer's Political Action Committee and is vice
chair of the Pfizer Foundation.
Sally directs Pfizer's global communications and its public affairs activities, including high-level relations with the governments of all nations in
which the Company has operations or markets products. Sally also heads the firm's corporate responsibility group and plays a key role in shaping the
Company's policy initiatives. Before joining Pfizer in 2007, Sally held roles at Estée Lauder Companies and the American Express Company. Earlier
in her career, she spent eight years in government service focused on international trade issues.
Sally serves on the board of WPP plc, a world leader in advertising and marketing based in the U.K., and as co-chair of the board of The
International Rescue Committee.

Johnson & Johnson
Ashley McEvoy, Executive Vice President
Worldwide Chairman, Medical Devices
Ashley McEvoy is Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson, and a member of the Executive Committee. In her role, Ashley
leads the surgery, orthopaedics, interventional solutions and eye health businesses, which generate approximately $27B in revenue. The Medical Devices sector employs
70,000 associates across Ethicon, DePuy Synthes, Biosense Webster and Johnson & Johnson Vision.
Ashley has been with Johnson & Johnson for more than 20 years and has served in leadership roles in Consumer and Medical Devices. She is a Credo-based leader who has
delivered above-market performance for all four multibillion-dollar global companies she has led, and she is particularly adept at designing turnaround strategies for
mission-critical businesses.
In 2006, Ashley co-led the integration of Pfizer Consumer Healthcare into McNeil, the largest acquisition Johnson & Johnson had done to date. She delivered above-market
results for the company’s global over-the-counter business, while advancing patient access through key innovations like the first-of-its-kind switch of Zyrtec® to OTC status.
In 2009, as the Worldwide President of Ethicon, Ashley ran the global wound management business and grew leadership share in sutures and hernia care while advancing key
innovations. She is a multifaceted leader, at home in operating rooms around the world, successful in leading consumer-facing brands and a proven architect of creating
winning teams, strong innovation pipelines and future-forward business models.
In her most recent role as Company Group Chairman for Johnson & Johnson Vision and a member of the Management Committee, Ashley and her team redefined Johnson &
Johnson’s position in eye health, one of the largest and most underserved need areas in healthcare today. Ashley prioritized business transformation through digital technology,
delivering world-class patient experiences in both online and offline environments. Under her leadership, the Vision team consistently delivered above-market growth, and
established a robust cadence of product innovation while developing new business models to meet changing market needs.
Ashley is the executive sponsor of the Open&Out employee resource group, which supports the LGBTQ community globally. Under her leadership, this group has advanced
Johnson & Johnson’s goal of having its workforce reflect the populations it serves, and created educational materials to improve understanding and create safe, inclusive work
environments, earning accolades from multiple external organizations.
Ashley’s accomplishments have been recognized by numerous business and philanthropic organizations, and she was named a “2012 Working Mother of the Year” by Working
Mother magazine.

Johnson & Johnson
Jennifer Taubert is Executive Vice President, Worldwide Chairman,
Pharmaceuticals
Jennifer Taubert is Executive Vice President, Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, the world’s largest health care company. She is a member of the
Corporation’s Executive Committee and leads the Pharmaceuticals Group Operating Committee.
Jennifer has been a leader in shaping Janssen’s global strategy of transformational medical innovation, successfully bringing to market critical new medicines that
significantly improve the lives of patients living with cancer, immune-related diseases, heart disease and diabetes, infectious diseases including HIV, pulmonary
hypertension and serious mental illness. Under her leadership Janssen has become the world’s third-largest innovative pharmaceutical business and remains a significant
contributor to Johnson & Johnson’s growth. Jennifer is also recognized as a champion of diversity and inclusion, which she sees as critical to insight, innovation and
business success.
Prior to being named to her current role, as Company Group Chairman, The Americas, Jennifer led businesses that were a major catalyst of Johnson & Johnson’s growth,
doubling in size and consistently outpacing the industry to become the number one pharmaceutical company in the U.S. and Canada. Jennifer joined Johnson & Johnson in
2005 to lead global commercial strategy for Internal Medicine in the Pharmaceuticals Group. Later, as President, Internal Medicine, she built a powerhouse new franchise in
cardiovascular and metabolic disease. Before joining Johnson & Johnson, Jennifer spent 18 years in positions of increasing scope and responsibility at Merck and Allergan.
Jennifer was named to Fortune magazine’s “Most Powerful Women” list the past four years, and received the National Association for Female Executives’ 2017 “Woman of
Achievement” award.
Jennifer represents Johnson & Johnson on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest trade association representing
biotechnology companies, academic institutions, state biotechnology centers and related organizations, and on the Executive Committee of the International Section of the
Pharmaceutical Research and Manufacturers of America (PhRMA). She also serves on the National Academy of Medicine’s Leadership Consortium: Collaboration for a
Value & Science-Driven Learning Health System, and on the Advisory Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of
Southern California.
Jennifer received a bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master of Business Administration from the Anderson
Graduate School of Management, University of California, Los Angeles.

Johnson & Johnson
Kathy Wengel, Executive Vice President &
Chief Global Supply Chain Officer
Kathy Wengel is Executive Vice President & Chief Global Supply Chain Officer for Johnson & Johnson, and a member of the company’s Executive Committee. A strong
developer of globally diverse teams, she leads a Supply Chain organization that brings healthcare products and services to more than a billion patients and consumers around
the world every day.
Kathy leads all aspects of Supply Chain across Johnson & Johnson’s three business sectors: Consumer Health, Medical Devices and Pharmaceuticals. Her responsibilities
include enterprise Supply Chain strategy, innovation and deployment, planning, sourcing, manufacturing, distribution and customer service. She also has corporatewide
responsibility for Quality & Compliance; Environmental Health, Safety & Sustainability; and Engineering & Property Services, including Real Estate, Facilities and Capital
Project Management.
Since joining Johnson & Johnson in 1988, her responsibilities have grown to include a variety of strategic leadership and executive positions across the enterprise, working in
multiple countries and roles within operations, quality, engineering, new product development and other business functions.
Prior to Kathy’s current role, she was Vice President, Quality & Compliance (Q&C), and the first Chief Quality Officer for Johnson & Johnson, with enterprise leadership
responsibility for Q&C, Sterility Assurance and Operations Readiness & Convergence. During this time, she also co-led the design of Johnson & Johnson’s enterprise Supply
Chain operating model that ultimately brought together more than twenty disparate groups using core standards and operating principles.
Kathy serves as Chairman of the Board of GS1 Global, an organization that sets and maintains standards regarding the exchange of critical business data. Kathy also sits on
the board of the National Association of Manufacturers in the US, and on the advisory board of AWESOME, a nonprofit working on the advancement of women in senior
supply chain roles. She is the executive sponsor for Johnson & Johnson’s Women’s Leadership & Inclusion initiative and for Johnson & Johnson’s Women in Science,
Technology, Engineering, Math, Manufacturing and Design (WiSTEM2D) program.
In 2019, Kathy was recognized by the Council of Supply Management Professionals (CSCMP) as the recipient of its Distinguished Service Award, the industry’s top
individual supply chain honor. In 2015, Kathy received both the National Association of Female Executives’ (NAFE) Women of Excellence Award and the Thinkers &
Movers Award for innovative leadership by DSC Logistics. In 2014, Kathy received AWESOME’s Legendary Leadership Award.
Kathy holds a BSE degree in civil engineering and operations research from Princeton University.

Abbvie
Laura J. Schumacher
Vice Chairman, External Affairs and Chief Legal Officer
Laura Schumacher was Executive Vice President, External Affairs, General Counsel and Corporate Secretary, responsible for Abbvies externally
facing functions of Health Economics Outcomes Research, Government Affairs, Corporate Responsibility, Brand and Communications. She also
leads all legal functions. Prior to AbbVie`s separation from Abbott, Ms. Schumacher served as Executive Vice President, General Counsel and
Secretary, where she also had responsibility for the Office of Ethics and Compliance. Both at Abbott and AbbVie, Ms. Schumacher has led Licensing
& Acquisitions and Ventures and Early Stage Collaborations. She serves on the board of General Dynamics.

Abbvie
Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Operations
Dr. Azita Saleki-Gerhardt is Executive Vice President, Operations, leading a team of scientiﬁc, engineering, business, quality, supply chain, security,
purchasing and manufacturing professionals responsible for supply and distribution of all AbbVie products, as well as a number of corporate services.
Dr. Saleki-Gerhardt joined Abbott in 1993 as a research scientist. She has worked in key leadership positions of increasing responsibility across a broad
range of areas, including science and technology, manufacturing and quality assurance. Following AbbVie’s separation from Abbott, Dr. Saleki-Gerhardt
was appointed head of AbbVie Operations.
She has been published in a number of scientiﬁc publications and has been awarded several patents related to pharmaceutical sciences.
Dr. Saleki-Gerhardt is a member of the Board of Directors for Entegris. She is a member of the Dean’s Advisory Boards for the School of International
Studies and School of Pharmacy at UW-Madison. At AbbVie, she is the executive chair of the Women Leaders in Action Employee Resource Group.
Dr. Saleki-Gerhardt earned her bachelor’s, master’s and doctorate degrees in pharmaceutics from the University of Wisconsin at Madison, U.S.A.

Novartis
Shannon Thyme Klinger
Group General Counsel
Shannon Thyme Klinger has been Group General Counsel of Novartis since 2018. She is a member of the Executive Committee of
Novartis.
Ms. Klinger most recently served as Chief Ethics, Risk and Compliance Officer from April to May 2018, and was appointed to the
Executive Committee of Novartis in this role. Before that, she was Chief Ethics and Compliance Officer and Global Head of Litigation
from 2016 to 2018. She joined Novartis in 2011 as General Counsel for North America at Sandoz Inc., and later served as General
Counsel and Global Head of Legal at Sandoz International from 2012 to 2016. Prior to Novartis, Ms. Prior to Novartis, Ms. Klinger
worked in the United States as a partner at Mayer Brown LLP from 2010 to 2011, and as general counsel and senior vice president at Solvay
Pharmaceuticals Inc. from 2008 to 2010.
Ms. Klinger holds a juris doctor with honors from the University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the
University of Notre Dame (both in the US). She is a member of the State Bar of Georgia and of the District of Columbia Bar in the US, and serves
on the board of directors of the SIX Group in Switzerland.

Novartis
Susanne Schaffert, President, Novartis Oncology
Susanne Schaffert, Ph.D., has been President of Novartis Oncology since January 1, 2019. She is a member of the Executive Committee of Novartis.
Ms. Schaffert was appointed Chairperson and President of Advanced Accelerator Applications when it was acquired by Novartis in January 2018.
She joined Novartis more than 20 years ago and served as General Manager of Europe for Novartis Oncology from 2012 to 2018. Prior to that, she
was Global Head of Investor Relations for Novartis from 2010 to 2012. She has also held other leadership positions during her career at Novartis,
including Global Franchise Head for Immunology and Infectious Diseases from 2009 to 2010, General Manager of Northern and Central Europe for
Novartis Oncology from 2007 to 2009, and General Manager of Germany for Novartis Oncology from 2004 to 2007.
Ms. Schaffert holds a doctorate in organic chemistry from the University of Erlangen in Germany. She serves on the boards of Novartis AG Germany
and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in Belgium. From 2015 to 2018, she represented Novartis on
the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd.

Novartis
Marie-France Tschudin, President,
Novartis Pharmaceuticals
Marie-France Tschudin has been President of Novartis Pharmaceuticals since June 7, 2019. She is a member of the
Executive Committee of Novartis.
Ms. Tschudin previously was President of Advanced Accelerator Applications, a Novartis company, from March to June
2019. She joined Novartis in 2017 as Europe Region Head of Novartis Pharmaceuticals, and has more than 25 years
of broad, multinational experience in the pharmaceutical and biotech industry. During her career, she has established a
strong record of accomplishments in driving commercial excellence, integrity, and commitment to patients. Before
joining Novartis, Ms. Tschudin spent 10 years at Celgene International in a variety of leadership positions, including
corporate vice president of hematology and oncology for Europe, the Middle East and Africa from 2014 to 2016;
regional vice president of northern Europe from 2012 to 2014; general manager of Austria, Switzerland, the Czech
Republic, Poland, Slovenia and Slovakia from 2009 to 2011; and country manager of Switzerland from 2008 to 2009.
Ms. Tschudin holds a Master of Business Administration from IMD business school in Switzerland, and a Bachelor of
Science from Georgetown University in the United States.

Novartis
Natacha Theytaz, Global Head, Novartis Business
Assurance & Advisory, Head, Internal Audit
Natacha Theytaz has been Global Head of Novartis Business Assurance & Advisory since January 1, 2019, and Head of Internal
Audit since 2018.
From 2010 to 2018, Ms. Theytaz was chief audit and risk advisory executive at F. Hoffmann-La Roche AG, where she was
responsible for four global functions: Internal Audit, Integrated Risk Management, Internal Investigations and Financial Compliance.
Prior to that, she was an audit director at F. Hoffmann-La Roche Ltd. from 2008 to 2010, a senior manager at Ernst & Young Advisory
from 2005 to 2008, and a senior internal auditor and project manager at F. Hoffmann-La Roche Ltd. from 2002 to 2005. She has also
worked as an advisor at the Swiss State Secretariat for Economic Affairs (2001-2002) and as a consultant at Roland Berger (2001).
Ms. Theytaz received an executive diploma in commercial law from the University of St.Gallen in Switzerland; a Master of Advanced
European Studies in economics, law and political science from the University of Basel in Switzerland; and a bachelor’s degree in
social sciences from the University of Lausanne in Switzerland. She serves on the board of EuroAirport Basel-Mulhouse-Freiburg and
previously was a regulatory board member of the SIX Swiss Exchange from 2017 to 2018.

Merck
Julie Gerberding, Executive Vice President, Chief Patient Officer,
Strategic Communications, Global Public Policy & Population
Health
Julie L. Gerberding, M.D., M.P.H., is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and
Population Health at Merck & Co., Inc., where she also has responsibility for the “Merck for Mothers” global program to prevent maternal mortality
and the Merck Foundation. She joined Merck in January 2010 as president of Merck Vaccines and led efforts to make the company’s vaccines more
available and affordable to people in resource-limited countries around the world. She left her tenured faculty position at the University of California,
San Francisco in 1998 to lead the U.S. Centers for Disease Control and Prevention (CDC) Division of Healthcare Quality Promotion and then served
as the CDC Director from 2002 to 2009. As director, she led the CDC through more than 40 emergency responses to public health crises, including
anthrax bioterrorism, SARS, and natural disasters. She also advised governments around the world on urgent issues such as pandemic preparedness,
AIDS, antimicrobial resistance, tobacco, and cancer. Dr. Gerberding currently serves on the Boards of CWRU, National Association of City and
County Health Officials (NACCHO) Foundation, MSD Wellcome Trust Hilleman Laboratories, and the BIO Executive Committee. She has received
more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for
her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. She was named to Forbes Magazine's 100 Most Powerful
Women in the World in 2005 through 2008 and to TIME Magazine's 100 Most Influential People in the World in 2004.

Merck
Jennifer Zachary, Executive Vice President, General Counsel
Jennifer Zachary is Executive vice president and general counsel with Merck & Co., Inc (2018- Present. Prior to this role, Zachary was a partner at
Covington & Burling in the firm’s food, drug, and device practice group where she advised a wide range of manufacturers and industry trade
associations on FDA’s requirements for the development, manufacture, and distribution of prescription and over-the-counter drugs, biologics, and
medical devices. Zachary began her career in FDA’s Office of Chief Counsel, where she served as an Associate Chief Counsel for Enforcement from
2005 to 2011. Zachary also served as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney’s Office for the District of
Columbia.
She received her J.D. from Harvard Law School (2004) and earned her undergraduate from Arizona State in 2001.

Sanofi
Caroline Luscombe, Executive Vice President,
Human Resources
Caroline Luscombe holds a bachelor’s degree in German from University College, London. She started her career in ﬁnance at Arthur
Young McClelland Moore, and was also UK controller and Compensation and Beneﬁts manager for the strategy consultants Bain &
Company.Until recently, she was Head of Organization and Human Resources and a member of the Executive Committee at
LafargeHolcim, based in Zurich (Switzerland). Before joining LafargeHolcim, she spent six years as Global Head of Human Resources
and a member of the Executive Committee at Syngenta.She previously held a number of senior HR positions at General Electric (GE),
including head of HR at GE Capital Global Banking, GE Money and GE Healthcare Bio-Sciences. Ms Luscombe was also Executive
Vice President HR for the Medical Diagnostics Division of Amersham plc, before that company was acquired by GE.She was appointed
to her actual position on October 1, 2018.Caroline Luscombe is a citizen of the United Kingdom.

Sanofi
Kathleen Tregoning, Executive Vice President,
External Affairs
Kathleen Tregoning received her Bachelor’s degree in International Relations from Stanford University and her master’s degree in Public Policy from the
Kennedy School of Government at Harvard University.She has more than 20 years of professional experience in policy, advocacy, stakeholder outreach
and external engagement. She began her career in 1993 with Andersen Consulting in San Francisco and later served as a Policy Advisor and then
Assistant Deputy Mayor in the Office of the Mayor for the City of Los Angeles.In 2001, Kathleen moved to Washington DC where she served as a
professional staff member in the US Congress, working for the chairmen of the House of Representatives Ways & Means Committee, the House Energy
& Commerce Committee, and the Senate Budget Committee. In these positions she was a key resource for members of Congress on a wide range of
health care issues including Medicare, Medicaid, prescription drugs, disease management, health care information technology, and post-acute
care.Kathleen joined Biogen in 2006 as Vice President, Public Policy & Government Affairs.

Severine Lacourt
Chief of Staff to the Chief Executive Officer
Severine Lacourt
Chief of Staff to the Chief Executive Officer
As Chief of Staff to the Chief Executive Officer, Severine Lacourt supports the office of the CEO and plays a strategic role driving enterprise
initiatives.
Severine has more than 20 years of biopharmaceutical industry experience in the fields of marketing, sales, strategy, business unit management
and strategic project management, spanning U.S. and international assignments.
She joined the company in 2010, most recently serving as Worldwide Biomarkers Commercialization Lead, and prior to this Worldwide
Commercial Lead for Hematology. Before joining Bristol-Myers Squibb, Severine held positions with Johnson & Johnson, Sanofi, GSK and
Boston Consulting Group.
Severine earned her MBA from INSEAD and a degree in business and entrepreneurship from HEC School of Management in Paris.

Sandra Leung
Executive Vice President, General Counsel
Sandy Leung serves as legal advisor to the Board of Directors and company executives, and is responsible for shaping the company’s legal strategy.
Sandy is also responsible for Environment, Health & Safety & Sustainability, Corporate Security and Philanthropy.
“The accelerating pace of science, governmental policies and regulations and overall global complexity across our industry requires us to be even more
agile than ever,” says Sandy. “Our legal team brings strategic value across all aspects of our business through practical and sound counsel that guide our
company in its mission to help patients.”
Sandy joined Bristol-Myers Squibb in 1992 as a staﬀ attorney in the litigation department. In 1996, she became assistant counsel and one year later, was
named associate counsel. In 1999, Sandy was appointed to the position of counsel and corporate secretary. In 2006, she was appointed acting general
counsel and in 2007, she was named general counsel. In 2014, Sandy was named executive vice president.
Prior to joining the company, Sandy was a prosecutor in the Manhattan District Attorney’s Oﬃce.
“My advice to those aspiring to management positions is to be good at what you do. You have to be willing to do the hard work and bring good excellent
judgment and expertise to the table. Most important, you must have great personal integrity and be someone people can trust. If people trust you, they
will feel comfortable seeking your advice. Also, be respectful of people, not just your superiors but everyone.”
Sandy earned her law degree from Boston College of Law and her bachelor’s degree from Tufts University.

Kathryn Metcalfe is Executive Vice President,
Corporate Affairs
Kathryn Metcalfe is Executive Vice President, Corporate Affairs. She is responsible for leading the company’s strategic communications across
stakeholder groups, including internal and external communications, global advocacy, state and federal government affairs, and global policy.
“It’s an exciting time for BMS,” said Kathryn. “Following the acquisition of Celgene, the combined company has the pipeline, people and potential to
transform patients' lives through science. As an industry leader, it will be important to work with multiple, diverse stakeholders to share the promise of
our future.”
Kathryn is a seasoned communication professional who has held multiple leadership positions at major corporations and top agencies. She has been
recognized by her peers as an innovator and was inducted into the PRWeek Hall of Femme, in addition to being included on several industry lists of top
communicators.
Kathryn joined BMS from CVS Health, one of the nation’s largest health companies, where she was Chief Communications Officer following the
company’s acquisition of Aetna, Inc. Kathryn served as Aetna’s Chief Communications Officer. Previously, Kathryn was Chief Communications Officer
of Deloitte LLP and held senior communications roles at Pfizer Inc. and Novartis Pharmaceuticals Corporation. Kathryn started her career working for
communications consultancies in the biotechnology and healthcare industries.
Kathryn holds master’s and bachelor’s degrees in journalism from Northwestern University and was an adjunct professor at New York University. She is
on the Board of the Quell Foundation, Boise Urban Garden School (BUGs) and built a park in her hometown of Boise, Idaho.

Ann M. Powell is the Global Head of Human Resources
Ann M. Powell is the Global Head of Human Resources with direct responsibility for driving the corporation’s global capabilities in talent management,
culture and organizational effectiveness tied directly to business performance.
Ann works across the enterprise to support Bristol-Myers Squibb's commitment to creating an energizing work experience and a culture that is powerfully
diverse and broadly inclusive, where individuals are encouraged to exceed their potential and inspired to make innovative contributions for our patients
and the global communities in which they live and work.
“The courage and passion of our workforce is truly inspiring and drives an even higher level of engagement in making a difference in the lives of patients”
says Ann.
Ann’s industry experience and expertise lie in executive compensation, leadership development, change management, diversity/inclusion, training design
and delivery, talent acquisition, labor relations, mergers and acquisitions, divestitures and start-ups.
With a career spanning both international and domestic assignments, Ann has held leadership roles of increasing responsibility within both the chemical
and pharmaceutical industries, including Dow Chemical and Wyeth Pharmaceuticals. Prior to joining Bristol-Myers Squibb in 2013, Ann was the Chief
Human Resources Officer for Shire Pharmaceuticals.
Ann earned a bachelor’s degree from Iowa State University and a master’s degree in Industrial Relations from the University of Minnesota.

CeLois Steele Director Global Diversity & Inclusion Partnership Engagement
CeLois Steele is Global Diversity & Inclusion Partnership Engagement Lead for the Bristol-Myers Squibb Company. Leveraging corporate and
non-profit partnerships, she is responsible for building, driving and management of BMS’s external reputation as a “trusted partner” focused on
“meeting the unmet medical needs of patients worldwide” through the management of innovative global/national partnerships within communities
worldwide. CeLois has worked across the private, public and non-profit sectors and has more than 20 years of leadership and management
experience in diversity & inclusion, community marketing, philanthropy, community engagement and non-profit partnership management. Her
career as both a corporate and non-profit leader has focused on strategic programs and initiatives in health, education, workforce development, and
cause related marketing. She has earned a reputation for leadership, innovation, commitment, and results, evidenced by her holding P&L roles at
companies such as IBM, General Mills, Carlson and leading teams at non-profits such as United Way and Girl Scouts, Inc.

Roche,
Cristina Wilbur, Group Human Resources
Cristina A. Wilbur is Chairman of International School of the Basel Region AG and Head-Group Human Resources at Roche Holding AG.
In the past she occupied the position of Global Head-Human Resources & Senior VP at Roche Diagnostics (Switzerland) AG, Head-Group
Human Resources at Roche Group, Director-Human Resources at EG&G, Inc., Director-Human Resources of PerkinElmer Optoelectronics, Inc.
and Director-Human Resources at Roche Diagnostics Corp.
Cristina A. Wilbur received an undergraduate degree from California Polytechnic State University (San Luis Obispo).

SGA Talent’s Example of an Organization Chart Showing Diversity
Diversity Matters. Be sure to emphasis the importance of diversity as it relates to the talent pool and candidate pipeline 518 843-4611
www.sgatalent.com

SGA Talent
Recruiting Scorecard
January 2020
Partner: Specialty Pharmaceutical Company
SGA Talent - A True Recruiting Partner
No Role is too big or too small for our partners!
Titles & Base Salary Information
Senior Director, Managed Care ($230,000)
Director of Consumer Marketing ($215,000)
Associate Director, Drug Safety & Pharmacovigilance
($140,000)
Senior Manager Clinical Operations ($150,000)
Executive Assistant to Chief Executive Oﬃcer ($90,000)
Average Cost Per Hire: 7% (base salary)
Timeframe: 3 Months
www.sgatalent.com 518 843-4611

SGA Talent
We Look forward to assisting you with your
talent and talent intelligence needs
518 843-4611
www.sgatalent.com

SGA Talent Providing All the Talent & Intelligence to
Get You There…….

SGA Talent Present Women Leader From The Top BioTech & Pharma Companies.

Recommandé

Recommandé

Contenu connexe

Similaire à SGA Talent Present Women Leader From The Top BioTech & Pharma Companies.

Similaire à SGA Talent Present Women Leader From The Top BioTech & Pharma Companies. (20)

Plus de SGA Talent

Plus de SGA Talent (20)

SGA Talent Present Women Leader From The Top BioTech & Pharma Companies.